Cardiovascular health during and after cancer therapy

Kathryn J. Ruddy, Shruti R. Patel, Alexandra S. Higgins, Saro H. Armenian, Joerg Herrmann

Research output: Contribution to journalReview articlepeer-review

Abstract

Certain cancer treatments have been linked to specific cardiovascular toxicities, including (but not limited to) cardiomyopathy, atrial fibrillation, arterial hypertension, and myocarditis. Radiation, anthracyclines, human epidermal growth factor receptor 2 (Her2)-directed therapies, fluoropyrimidines, platinums, tyrosine kinase inhibitors and proteasome inhibitors, immune checkpoint inhibitors, and chimeric antigen-presenting (CAR)-T cell therapy can all cause cardiovascular side effects. Management of cardiovascular dysfunction that occurs during cancer therapy often requires temporary or permanent cessation of the risk-potentiating anti-neoplastic drug as well as optimization of medical management from a cardiovascular standpoint. Stem cell or bone marrow transplant recipients face unique cardiovascular challenges, as do patients at extremes of age.

Original languageEnglish (US)
Article number3737
Pages (from-to)1-16
Number of pages16
JournalCancers
Volume12
Issue number12
DOIs
StatePublished - Dec 2020

Keywords

  • Anthracycline
  • Cardio-oncology
  • Congestive heart failure
  • Myocarditis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cardiovascular health during and after cancer therapy'. Together they form a unique fingerprint.

Cite this